{"id":"W4409255592","doi":"10.1182/blood.2024024476","title":"Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Manitoba; Research Institute in Oncology and Hematology; CancerCare Manitoba","funders":"National Comprehensive Cancer Network; Gilead Sciences; AstraZeneca; National Cancer Institute; National Institutes of Health; Pfizer","keywords":"Obinutuzumab; Chlorambucil; Medicine; Internal medicine; Chronic lymphocytic leukemia; Oncology; Leukemia; Chemotherapy; Cyclophosphamide","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001219055,0.0003265416,0.0008644463,0.0002172621,0.0002798247,0.0006120472,0.0002577028,0.0004125682,0.001090341],"category_scores_gemma":[0.0007941588,0.0001295498,0.0009225612,0.0002825266,0.0001961097,0.0004422031,0.0002158317,0.0007678637,0.0002076783],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006048768,"about_ca_system_score_gemma":0.0004570213,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009796848,"about_ca_topic_score_gemma":0.002322813,"domain_scores_codex":[0.9996639,0.0001298394,0.00002396088,0.00005952353,0.00004379695,0.00007888452],"domain_scores_gemma":[0.9994553,0.000125886,0.0001721679,0.00004162075,0.00003487401,0.0001701322],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5763643,0.01300857,0.2316674,0.0002736281,0.002412581,0.0004346567,0.0002327684,0.002160495,0.0257803,0.0001054844,0.002503765,0.145056],"study_design_scores_gemma":[0.04301765,0.1885519,0.7457557,0.00009746877,0.003126912,0.0009458098,0.0001794565,0.005334534,0.008596935,0.0002562473,0.004084993,0.00005239715],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9984556,0.0009715132,0.0000513048,0.00005383151,0.00001917319,0.00002299496,0.0001586132,0.000007718081,0.0002591741],"genre_scores_gemma":[0.9989657,0.0002378253,0.00006105081,0.00007082011,0.00002717145,0.00002598009,0.000408037,0.000001587626,0.0002018574],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001219055,"threshold_uncertainty_score":0.006447017,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01805478524415328,"score_gpt":0.3061912271200667,"score_spread":0.2881364418759135,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}